Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT00425867
Other study ID # PAR1 polymorphisms
Secondary ID
Status Not yet recruiting
Phase N/A
First received January 22, 2007
Last updated January 25, 2007
Start date March 2007
Est. completion date November 2007

Study information

Verified date January 2007
Source Shaare Zedek Medical Center
Contact Sorina Grisaru, MD
Phone 97226555111
Email granovsky@netvision.net.il
Is FDA regulated No
Health authority Israel: Ministry of Health
Study type Observational

Clinical Trial Summary

The present study will be undertaken to establish whether genetic variations of PAR1 could be involved in the occurrence of any of the "placental syndromes" of preterm delivery, preeclampsia, and/or small for gestational age babies and recurrent pregnancy loss.


Description:

Polymorphisms of Protease Activated Receptor 1 and adverse pregnancy outcomes Protease Activated Receptor 1 (PAR1), the main thrombin receptor on vascular cells (Coughlin,1999), plays a critical role in orchestrating human placentation based on temporally and spatially constrained PAR1 expression in the normal invasive trophoblasts (O’Brien et al, 2003) and its overexpression in pathological invasive trophoblast (Even-Ram et al, 2003).

Various proteases of the PAR family as well as matrix metalloproteinases have been implicated in ancillary regulation of cancer metastases and tumor-related angiogenesis. PAR1 in particular has been proposed to be involved in invasive processes of various cancers (Ruf & Mueller, 2006; Boire et al, 2005). Similarly, it might be surmised that remodeling of the placenta microenvironment as well as the requisites of trophoblast invasiveness may be PAR1 sensitive (Grisaru-Granovsky et al, 2005). Therefore, one might hypothesize that PAR1 gene variability may be involved in early placentation and that adverse pregnancy outcomes of the "placental syndromes" may have their origin in PAR1 dysregulation.

Study Design: This is a prospective case-control pilot study. Subject enrolment and data collection will be performed via the Admission Service of the Division for Maternal & Fetal Medicine in a large tertiary obstetrics department in Jerusalem, Israel. Demographic data including maternal characteristics, past reproductive history, and information about previous complications during pregnancy, delivery and the neonatal period will be culled. The blood samples will be collected at routine admission after obtaining informed consent by the physician on the floor.

Four groups are described: patients with spontaneous preterm delivery of a singleton before 35 weeks of gestation; patients with a singleton pregnancy complicated by preeclampsia diagnosed according the Working Group Criteria (2000); patients who deliver a small for gestational age (SGA) singleton defined as a birth weight below the 10th percentile for the gestational age according to the Israeli growth curves (Dollberg et al, 2005); and for comparison, patients who deliver a singleton at term with appropriate size for gestational age. Patients who suffer delivery with intrauterine fetal demise and/or neonates with malformations will be excluded.

Maternal and umbilical cord blood samples (in 0.11mol/l sodium tri citrate) will be paired. DNA will be prepared from white blood cells by standard techniques and subsequently stored at -4°C for batched analysis. The laboratory staff will be blinded as to the clinical status of the samples.

Polymorphism analysis will be performed for the following polymorphisms of the PAR1 gene: [-1426CT], [506 insertion of 13 bp],[IVS-14A/T]: as per standard PCR techniques using appropriate restriction endonucleases (Arnaud et l, 2000).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date November 2007
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 40 Years
Eligibility Inclusion Criteria:

- Women with reccurent abortions unexplained

- Premature delicery

Exclusion Criteria:

- Term pregnancies

- Abortion that the cause is known

Study Design

Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional


Intervention

Behavioral:
PAR1 polymoprhisms and placental invasion


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Shaare Zedek Medical Center
See also
  Status Clinical Trial Phase
Completed NCT00457925 - Absorption, Distribution, Metabolism And Excretion Study For GSK221149A Phase 1
Completed NCT05602883 - Music Therapy in the Threat of Premature Birth N/A
Completed NCT02451228 - Indomethacin PK and PD Therapy in Pregnancy
Terminated NCT00306462 - Trial of Magnesium Sulfate Tocolysis Versus Nifedipine Tocolysis in Women With Preterm Labor N/A
Completed NCT02793700 - Pharmacokinetics (PK) and Modeling of Betamethasone Therapy in Threatened Preterm Birth
Completed NCT00873314 - Bed Rest for Threatened Preterm Labor. Pilot Study N/A
Withdrawn NCT00120640 - Treatment of Preterm Labor With 17 Alpha-hydroxyprogesterone Caproate N/A
Completed NCT03223324 - Performance of the Monica Novii Wireless Patch System in Threatened and Actual Pre-Term Labour
Not yet recruiting NCT01022619 - The Association Between High Risk Pregnancy and Sleep-disordered Breathing N/A
Withdrawn NCT02569216 - Electrical Inhibition (EI): A Preliminary Study To Inhibit Preterm Labor And Preterm Birth Phase 1
Recruiting NCT05477381 - Cervical Softening and the Prediction of Preterm Birth
Completed NCT03057275 - Performance of the Monica Novii Wireless Patch System in Pre-term Labor

External Links